Biotech and Pharmaceutical Patents at the Federal Circuit
Tara and Peter will provide their views on several federal court decisions including: Section 101 patent eligibility of human genes under Myriad, Section 102 novelty and prior public use of drugs under Pronova Biopharma, Written Description of enzyme variants under Novozymes, Patent Exhaustion under Bowman, parallel litigation and reexamination strategies under Fresenius, and more. They will put these cases into context and provide important advice on how they may impact both your prosecution and litigation strategies.